Attendance an online digital event on Dec. 05, 2024 entitled “Use of doxycycline for the prevention of bacterial sexually transmitted infections (STIs) (DoxyPEP): Supporting evidence and the challenge of antimicrobial resistance (AMR)”. The event was offered by International Pharmaceutical Federation (FIP).

Description: The rising incidence of bacterial sexually transmitted infections (STIs), particularly among men who have sex with men, prompted the expanded preventive use of doxycycline as Post-Exposure Prophylaxis (DoxyPEP). Experts, however, suggested that this approach could also benefit individuals beyond this specific group.

Concerns were raised regarding antimicrobial resistance and the frequent, potentially inappropriate, use of antibiotics by those adopting this intervention. This event aimed to inform pharmacists about the evidence supporting the rational application of this strategy and to examine the potential public health implications of its widespread use.

Moderator:

Darija Kuruc Poje, Hospital pharmacist - Vice-president EAHP

EAHP - European association of hospital pharmacists, Croatia.

Co-Moderator:

Ria Benko, Chief pharmacist University of Szeged, Hungary.

Panellists:

- Laura Bachmann, Chief Medical Officer Centers for Disease Control and Prevention, National Center for HIV, Viral Hepatitis, STD and TB Prevention, Division of STD Prevention, United States.

- Thibaut Vanbaelen, Medical Doctor and Researcher Institute of Tropical Medicine, Antwerp, Belgium.

- Fabian Kong, Deputy Head, Sexual Health Unit Centre for Epidemiology and Biostatistics Melbourne School of Population and Global Health. The University of Melbourne, Australia.